Article
12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers

  • CASI Pharmaceuticals (NASDAQ:CASI) shares rose 54.2% to $0.32 during Wednesday's after-market session. The company's market cap stands at $12.3 million.
  • Curanex Pharmaceuticals (NASDAQ:CURX) stock moved upwards by 8.62% to $0.34. The market value of their outstanding shares is at $8.5 million.
  • Jyong Biotech (NASDAQ:MENS) stock increased by 7.43% to $2.6. The company's market cap stands at $209.8 million.
  • Arcutis Biotherapeutics (NASDAQ:ARQT) shares moved upwards by 7.11% to $28.93. The market value of their outstanding shares is at $3.3 billion. As per the news, the Q4 earnings report came out today.
  • Ernexa Therapeutics (NASDAQ:ERNA) shares rose 5.29% to $0.31. The company's market cap stands at $8.1 million.
  • Quince Therapeutics (NASDAQ:QNCX) shares increased by 2.87% to $0.14. The market value of their outstanding shares is at $7.7 million.

Losers

  • PROCEPT BioRobotics (NASDAQ:PRCT) stock decreased by 10.4% to $24.94 during Wednesday's after-market session. The company's market cap stands at $1.5 billion. The company's, Q4 earnings came out today.
  • Jaguar Health (NASDAQ:JAGX) shares decreased by 4.6% to $0.83. The market value of their outstanding shares is at $3.0 million.
  • ProMIS Neurosciences (NASDAQ:PMN) stock fell 4.34% to $19.0. The market value of their outstanding shares is at $38.6 million.
  • Lantern Pharma (NASDAQ:LTRN) stock decreased by 4.19% to $2.75. The company's market cap stands at $28.7 million.
  • Agilon Health (NYSE:AGL) shares declined by 3.98% to $0.48. The market value of their outstanding shares is at $163.2 million. The company's, Q4 earnings came out today.
  • Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares decreased by 3.96% to $5.1. The market value of their outstanding shares is at $6.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments
  • No comments yet. Be the first to comment!